NASDAQ:CMRX - Chimerix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.65 -0.04 (-0.85 %)
(As of 05/24/2018 05:59 AM ET)
Previous Close$4.69
Today's Range$4.63 - $4.80
52-Week Range$4.17 - $5.94
Volume340,988 shs
Average Volume142,926 shs
Market Capitalization$223.96 million
P/E Ratio-3.08
Dividend YieldN/A
Beta1.26

About Chimerix (NASDAQ:CMRX)

Chimerix logoChimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Debt-to-Equity RatioN/A
Current Ratio18.21
Quick Ratio18.21

Price-To-Earnings

Trailing P/E Ratio-3.08
Forward P/E Ratio-2.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.49 million
Price / Sales49.45
Cash FlowN/A
Price / CashN/A
Book Value$4.31 per share
Price / Book1.08

Profitability

EPS (Most Recent Fiscal Year)($1.51)
Net Income$-70,980,000.00
Net Margins-1,736.95%
Return on Equity-31.97%
Return on Assets-30.64%

Miscellaneous

Employees82
Outstanding Shares47,750,000

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) posted its earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.01. The biopharmaceutical company had revenue of $0.79 million for the quarter, compared to analyst estimates of $1.12 million. Chimerix had a negative net margin of 1,736.95% and a negative return on equity of 31.97%. View Chimerix's Earnings History.

When is Chimerix's next earnings date?

Chimerix is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Chimerix.

What price target have analysts set for CMRX?

3 brokers have issued 12 month price targets for Chimerix's shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Chimerix's share price to reach $8.00 in the next twelve months. View Analyst Ratings for Chimerix.

What are Wall Street analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:
  • 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (5/7/2018)
  • 2. HC Wainwright analysts commented, "Data from AdVance Make Us More Confident in the Potential Success of AdAPT; Reiterate Buy Strong correlation between mortality and adenovirus (AdV) burden. This morning, Chimerix announced data from the AdVance study, which was conducted to investigate AdV incidence, natural history, management and clinical outcomes in allogeneic hematopoietic cell transplant (allo-HCT) recipients. This large multi-center study, which was conducted in 2017, examined the incidence, practice patterns, hospitalization and clinical outcomes of 4,276 allo-HCT recipients, which included 1,738 pediatric patients and 2,538 adults. Results among the pediatric allo-HCT patients in the study demonstrated that highest mortality was observed in recipients with the greatest AdV burden, with 52% mortality in the patient quartile with highest time-averaged area under the curve (AAUC) compared to 3% mortality reported in the patient quartile with lowest AAUC." (3/19/2018)

Who are some of Chimerix's key competitors?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:
  • Dr. M. Michelle Berrey, Pres, CEO & Director (Age 51)
  • Mr. Timothy W. Trost, Sr. VP, CFO, Principal Accounting Officer & Corp. Sec. (Age 60)
  • Ms. Linda M. Richardson, Chief Strategy & Commercial Officer (Age 54)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 49)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer

Has Chimerix been receiving favorable news coverage?

News stories about CMRX stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Chimerix earned a coverage optimism score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Chimerix's major shareholders?

Chimerix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (7.81%), BlackRock Inc. (7.20%), Dimensional Fund Advisors LP (4.85%), Victory Capital Management Inc. (0.60%), Millennium Management LLC (0.53%) and Schwab Charles Investment Management Inc. (0.39%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, Linda M Richardson and M Michelle Berrey. View Institutional Ownership Trends for Chimerix.

Which major investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Granite Investment Partners LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold Chimerix company stock in the last year include Ernest Mario and Linda M Richardson. View Insider Buying and Selling for Chimerix.

Which major investors are buying Chimerix stock?

CMRX stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Millennium Management LLC, A.R.T. Advisors LLC, Victory Capital Management Inc., MetLife Investment Advisors LLC, Quantitative Systematic Strategies LLC, Alps Advisors Inc. and Wells Fargo & Company MN. Company insiders that have bought Chimerix stock in the last two years include Ernest Mario and M Michelle Berrey. View Insider Buying and Selling for Chimerix.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $4.65.

How big of a company is Chimerix?

Chimerix has a market capitalization of $223.96 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (CMRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chimerix (NASDAQ:CMRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Chimerix in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 72.04%. The high price target for CMRX is $10.00 and the low price target for CMRX is $6.00. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$7.6667$7.6667$6.50
Price Target Upside: 72.04% upside35.93% upside55.51% upside9.70% upside

Chimerix (NASDAQ:CMRX) Consensus Price Target History

Price Target History for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018HC WainwrightReiterated RatingBuy$10.00LowView Rating Details
3/1/2018CowenReiterated RatingHold$6.00LowView Rating Details
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLowView Rating Details
5/1/2017FBR & CoReiterated RatingHold$7.00HighView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Chimerix (NASDAQ:CMRX) Earnings History and Estimates Chart

Earnings by Quarter for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.80)
2019 EPS Consensus Estimate: ($1.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.44)($0.44)($0.44)
Q2 20181($0.44)($0.44)($0.44)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.47)($0.47)($0.47)
Q1 20191($0.48)($0.48)($0.48)
Q2 20191($0.48)($0.48)($0.48)
Q3 20191($0.44)($0.44)($0.44)
Q4 20191($0.49)($0.49)($0.49)

Chimerix (NASDAQ CMRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.44)N/AView Earnings Details
5/7/2018Q1 2018($0.43)($0.42)$1.12 million$0.79 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.48)($0.41)$0.83 million$1.84 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.43)($0.37)$0.81 million$0.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.41)($0.36)$1.28 million$0.68 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.38)$1.56 million$1.08 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.32)$0.89 million$1.98 millionViewListenView Earnings Details
11/7/2016Q3($0.39)($0.37)$1.73 million$0.65 millionViewListenView Earnings Details
8/8/2016Q2($0.51)($0.39)$1.98 million$1.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details
3/6/2015Q414($0.51)($0.52)$1.13 million$1.16 millionViewListenView Earnings Details
11/7/2014Q314($0.41)($0.47)$0.40 million$1.19 millionViewN/AView Earnings Details
8/7/2014Q214($0.46)($0.39)$0.84 million$0.92 millionViewN/AView Earnings Details
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details
3/7/2014Q413($0.41)($0.31)$1.19 million$0.8790 millionViewN/AView Earnings Details
11/14/2013Q3($0.38)($0.26)$1.28 million$0.91 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.8080 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Chimerix (NASDAQ:CMRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Chimerix (NASDAQ CMRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.50%
Institutional Ownership Percentage: 72.65%
Insider Trading History for Chimerix (NASDAQ:CMRX)
Insider Trading History for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ CMRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Ernest MarioDirectorSell45,000$4.80$216,000.0012,905View SEC Filing  
5/16/2018Ernest MarioDirectorSell30,000$4.79$143,700.0012,905View SEC Filing  
5/14/2018Ernest MarioDirectorSell52,553$4.64$243,845.9212,905View SEC Filing  
5/10/2018Ernest MarioDirectorSell2,815$4.60$12,949.0012,905View SEC Filing  
12/1/2017Linda M RichardsonInsiderSell19,833$4.47$88,653.51View SEC Filing  
12/28/2016Ernest MarioDirectorSell100,000$4.64$464,000.0012,905View SEC Filing  
9/15/2016John M LeonardDirectorSell5,000$5.03$25,150.00View SEC Filing  
8/29/2016M Michelle BerreyInsiderBuy22,417$4.47$100,203.99281,238View SEC Filing  
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00381,440View SEC Filing  
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72258,821View SEC Filing  
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00331,440View SEC Filing  
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00297,240View SEC Filing  
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00297,240View SEC Filing  
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00287,919View SEC Filing  
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00287,919View SEC Filing  
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.0010,000View SEC Filing  
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00262,637View SEC Filing  
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.004,000View SEC Filing  
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chimerix (NASDAQ CMRX) News Headlines

Source:
DateHeadline
Insider Selling: Chimerix Inc (CMRX) Director Sells 45,000 Shares of StockInsider Selling: Chimerix Inc (CMRX) Director Sells 45,000 Shares of Stock
www.americanbankingnews.com - May 21 at 4:08 PM
Zacks: Analysts Expect Chimerix Inc. (CMRX) Will Post Quarterly Sales of $940,000.00Zacks: Analysts Expect Chimerix Inc. (CMRX) Will Post Quarterly Sales of $940,000.00
www.americanbankingnews.com - May 18 at 6:15 AM
Chimerix Inc. (CMRX) Director Sells $143,700.00 in StockChimerix Inc. (CMRX) Director Sells $143,700.00 in Stock
www.americanbankingnews.com - May 17 at 1:21 PM
Recent Analysis Shows Camden Property Trust, Biglari, Argan, Chimerix, Workhorse Group, and Magellan Midstream ...Recent Analysis Shows Camden Property Trust, Biglari, Argan, Chimerix, Workhorse Group, and Magellan Midstream ...
www.nasdaq.com - May 17 at 9:37 AM
Form 4 CHIMERIX INC For: May 15 Filed by: MARIO ERNESTForm 4 CHIMERIX INC For: May 15 Filed by: MARIO ERNEST
www.streetinsider.com - May 16 at 4:34 PM
-$0.44 Earnings Per Share Expected for Chimerix Inc. (CMRX) This Quarter-$0.44 Earnings Per Share Expected for Chimerix Inc. (CMRX) This Quarter
www.americanbankingnews.com - May 16 at 1:09 AM
Insider Selling: Chimerix Inc. (CMRX) Director Sells 52,553 Shares of StockInsider Selling: Chimerix Inc. (CMRX) Director Sells 52,553 Shares of Stock
www.americanbankingnews.com - May 15 at 4:18 PM
Chimerix Inc. (CMRX) Director Ernest Mario Sells 2,815 SharesChimerix Inc. (CMRX) Director Ernest Mario Sells 2,815 Shares
www.americanbankingnews.com - May 11 at 8:38 PM
Q2 2018 EPS Estimates for Chimerix Inc. Lifted by Analyst (CMRX)Q2 2018 EPS Estimates for Chimerix Inc. Lifted by Analyst (CMRX)
www.americanbankingnews.com - May 10 at 7:08 AM
Chimerix Inc. Expected to Post Q1 2019 Earnings of ($0.48) Per Share (CMRX)Chimerix Inc. Expected to Post Q1 2019 Earnings of ($0.48) Per Share (CMRX)
www.americanbankingnews.com - May 9 at 9:06 AM
Chimerix Inc 2018 Q1 - Results - Earnings Call SlidesChimerix Inc 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 8 at 4:33 PM
Chimerix (CMRX) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSChimerix (CMRX) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 8 at 9:52 AM
Edited Transcript of CMRX earnings conference call or presentation 7-May-18 12:30pm GMTEdited Transcript of CMRX earnings conference call or presentation 7-May-18 12:30pm GMT
finance.yahoo.com - May 8 at 9:18 AM
Chimerix (CMRX) Stock Rating Lowered by Zacks Investment ResearchChimerix (CMRX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 7 at 8:22 PM
Form 10-Q CHIMERIX INC For: Mar 31Form 10-Q CHIMERIX INC For: Mar 31
www.streetinsider.com - May 7 at 4:42 PM
Chimerixs (CMRX) CEO Michelle Berrey on Q1 2018 Results - Earnings Call TranscriptChimerix's (CMRX) CEO Michelle Berrey on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 4:42 PM
Want To Invest In Chimerix Inc (NASDAQ:CMRX)? Here’s How It Performed LatelyWant To Invest In Chimerix Inc (NASDAQ:CMRX)? Here’s How It Performed Lately
finance.yahoo.com - May 7 at 4:42 PM
Form 8-K CHIMERIX INC For: May 07Form 8-K CHIMERIX INC For: May 07
www.streetinsider.com - May 7 at 9:12 AM
Chimerix: 1Q Earnings SnapshotChimerix: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 9:12 AM
Chimerix (CMRX) Rating Increased to Sell at ValuEngineChimerix (CMRX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 10:35 PM
Zacks Investment Research Upgrades Chimerix (CMRX) to "Buy"Zacks Investment Research Upgrades Chimerix (CMRX) to "Buy"
www.americanbankingnews.com - May 2 at 10:58 PM
Chimerix to Present at the Deutsche Bank 43rd Annual Health Care ConferenceChimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 9:20 AM
Chimerix Inc. (CMRX) Given Average Recommendation of "Hold" by AnalystsChimerix Inc. (CMRX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 30 at 9:47 AM
Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018
finance.yahoo.com - April 30 at 9:34 AM
Chimerix (CMRX) Scheduled to Post Earnings on MondayChimerix (CMRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 8:17 AM
Chimerix Inc. (CMRX) Expected to Announce Quarterly Sales of $1.12 MillionChimerix Inc. (CMRX) Expected to Announce Quarterly Sales of $1.12 Million
www.americanbankingnews.com - April 30 at 3:50 AM
-$0.43 EPS Expected for Chimerix Inc. (CMRX) This Quarter-$0.43 EPS Expected for Chimerix Inc. (CMRX) This Quarter
www.americanbankingnews.com - April 28 at 11:10 AM
 Brokerages Expect Chimerix Inc. (CMRX) Will Announce Quarterly Sales of $1.12 Million Brokerages Expect Chimerix Inc. (CMRX) Will Announce Quarterly Sales of $1.12 Million
www.americanbankingnews.com - April 13 at 2:52 AM
 Brokerages Anticipate Chimerix Inc. (CMRX) to Post -$0.43 Earnings Per Share Brokerages Anticipate Chimerix Inc. (CMRX) to Post -$0.43 Earnings Per Share
www.americanbankingnews.com - April 11 at 1:12 PM
Chimerix (CMRX) Downgraded by ValuEngineChimerix (CMRX) Downgraded by ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
Chimerix (CMRX) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowChimerix (CMRX) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:33 PM
Chimerix Inc. (CMRX) Receives Average Rating of "Hold" from AnalystsChimerix Inc. (CMRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 11:15 AM
Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceChimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 2 at 4:34 PM
Chimerix to Present at the HC Wainwright Annual Global Life Sciences ConferenceChimerix to Present at the HC Wainwright Annual Global Life Sciences Conference
globenewswire.com - April 2 at 9:52 AM
Look what Triangle woman just became chairwoman of a $250M companyLook what Triangle woman just became chairwoman of a $250M company
www.bizjournals.com - March 30 at 4:33 PM
BRIEF-Chimerix Announces Martha J. Demski As Board ChairBRIEF-Chimerix Announces Martha J. Demski As Board Chair
www.reuters.com - March 30 at 9:30 AM
Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of DirectorsChimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors
finance.yahoo.com - March 30 at 9:30 AM
$1.12 Million in Sales Expected for Chimerix Inc. (CMRX) This Quarter$1.12 Million in Sales Expected for Chimerix Inc. (CMRX) This Quarter
www.americanbankingnews.com - March 27 at 4:00 AM
 Analysts Anticipate Chimerix Inc (CMRX) to Post -$0.43 Earnings Per Share Analysts Anticipate Chimerix Inc (CMRX) to Post -$0.43 Earnings Per Share
www.americanbankingnews.com - March 25 at 1:16 PM
Durham pharma pushing to fight a common cold virus thats deadly to some patientsDurham pharma pushing to fight a common cold virus that's deadly to some patients
www.bizjournals.com - March 24 at 4:26 PM
Durham pharma pushing to fight a common cold virus that's deadly to some patientsDurham pharma pushing to fight a common cold virus that's deadly to some patients
finance.yahoo.com - March 23 at 9:23 AM
European, multi-center study reinforces need for effective therapies for adenovirus in immunocompromised patientsEuropean, multi-center study reinforces need for effective therapies for adenovirus in immunocompromised patients
globenewswire.com - March 20 at 9:36 AM
Chimerix (CMRX) Receives Buy Rating from HC WainwrightChimerix (CMRX) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 19 at 12:00 PM
The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality RiskThe AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk
finance.yahoo.com - March 19 at 9:35 AM
Chimerix (CMRX) Raised to "Strong-Buy" at BidaskClubChimerix (CMRX) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM
Chimerix Inc (CMRX) Given Average Recommendation of "Hold" by BrokeragesChimerix Inc (CMRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 11 at 9:48 AM
Chimerix (CMRX) Upgraded by BidaskClub to "Buy"Chimerix (CMRX) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 10 at 6:34 PM
-$0.43 EPS Expected for Chimerix Inc (CMRX) This Quarter-$0.43 EPS Expected for Chimerix Inc (CMRX) This Quarter
www.americanbankingnews.com - March 8 at 1:56 PM
Chimerix to Present at Cowen and Company 38th Annual Health Care ConferenceChimerix to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 9:30 AM
Chimerix (CMRX) Stock Rating Upgraded by Zacks Investment ResearchChimerix (CMRX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 6 at 8:36 PM

SEC Filings

Chimerix (NASDAQ:CMRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Chimerix (NASDAQ:CMRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Chimerix (NASDAQ CMRX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.